• About Us
    • Contact Us
    • Login
    • ObGFirst
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • COVID-19
About Us Contact Us Login ObGFirst
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • COVID-19
Grand Rounds

SARS-CoV-2 Antibody Testing Among NYC Healthcare Personnel: How Many are Seropositive?

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • Moscola et al. (JAMA, 2020) investigated the prevalence of SARS-CoV-2 antibodies among healthcare personnel (HCP) in NYC and the association with demographics, primary work location and type, and suspicion of virus exposure

METHODS:

  • Cohort study (April 20, 2020, to June 23, 2020)
  • Setting
    • 52 sites in large healthcare system in NYC
  • Participants
    • All HCP in system
  • Study design
    • RT-PCR testing was available (March 7, 2020) to any HCP who had COVID-19 symptoms or suspected exposure
    • During the study period, all HCP were offered free, voluntary antibody testing, regardless of symptoms
    • There were 7 different validated assays used
    • HCP reported demographics, primary work location, job function, direct patient care, work on a COVID or non-COVID unit, and their level of suspicion of virus exposure
    • Associations between seroprevalence and these variables was assessed using Poisson logistic regression
  • Primary outcome
    • Seroprevalence

RESULTS:

  • 46,117 HCPs were tested (65.1% of personnel)
    • Median age 42 (IQR 31.5 to 54.5) years | 73.7% women
    • 16.0% Black | 0.8% multiracial | 14.0% Hispanic HCP
    • 28.4% nurses | 9.3% physicians
  • Seroprevalence
    • 13.7% of the tested population were seropositive
  • Prior RT-PCR test
    • Seroprevalence in those with prior positive RT-PCR test: 93.5%
    • Seroprevalence in those with a prior negative RT-PCR test: 89.7%
  • No prior RT-PCR test
    • Seropositive: 9.0%
  • Working in COVID-19 units or in ICU
    • Association with seroprevalence present in bivariate analyses but not in multivariable analyses
  • In a fully adjusted model, the following were associated with seroprevalence
    • Previous positive PCR test result
      • Relative risk (RR) 1.52 (95% CI, 1.44 to 1.60; P < 0.001)
    • Reported high suspicion of virus exposure
      • Relative risk 1.23 (95% CI, 1.18 to 1.28; P < 0.001)

CONCLUSION:

  • In this study of HCP in a large health system NYC, seroprevalence was 13.7%
    • Similar to approximately 14% seroprevalence reported for the general population in New York State
  • Seropositivity was most associated with high suspicion of exposure and a prior positive RT-PCR test
  • Limitations
    • Different tests were used with different sensitivities and specificities
    • The time between RT-PCR and antibody testing was unknown and possibly too short to detect an antibody response
    • Only responses for ‘suspicion for exposure’ were collected | Source (e.g. community, hospital, home etc.) not obtained
  • The authors conclude

Providing HCP with data about their SARS-CoV-2 virus exposure is important so they can protect themselves, their patients, their colleagues, and their families

High levels of HCP-reported suspicion of virus exposure may be useful as an indication for SARS-CoV-2 testing 

Learn More – Primary Sources:

Prevalence of SARS-CoV-2 Antibodies in Health Care Personnel in the New York City Area

Get COVID-19 Research Summaries Direct to Your Phone, with ObGFirst

ObGFirst® – Try It Free! »

image_pdfFavoriteLoadingFavorite
< Previous
All Grand Rounds Posts
Next >

Related ObG Topics:

CDC Update: COVID-19 Infection Rate Among Healthcare Workers
COVID-19 Infection Rates in Healthcare Personnel: Data from Washington State
How Long Does It Take for COVID-19 Patients to Develop Antibodies?

Sections

  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • COVID-19

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site